PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Samsara Inc. (IOT)
33.600.80 (-2.33%)
33.44 - 34.57
31.40 - 61.90
7.61M / 5.95M (Avg.)
-152.73 | -0.22
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.34%
Revenue growth 1.25-1.5x CFLT's 6.47%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
9.70%
Gross profit growth similar to CFLT's 9.67%. Walter Schloss would assume both firms track common industry trends.
21.49%
EBIT growth above 1.5x CFLT's 13.42%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
21.49%
Operating income growth above 1.5x CFLT's 13.42%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
24.07%
Net income growth 1.25-1.5x CFLT's 17.53%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
23.00%
EPS growth 1.25-1.5x CFLT's 17.86%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
23.00%
Diluted EPS growth 1.25-1.5x CFLT's 17.86%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
1.07%
Share count expansion well above CFLT's 1.53%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.07%
Diluted share count expanding well above CFLT's 1.53%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
54.00%
OCF growth at 50-75% of CFLT's 81.76%. Martin Whitman would question if the firm lags in monetizing sales effectively.
80.96%
FCF growth under 50% of CFLT's 244.67%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
-4.16%
Negative 10Y revenue/share CAGR while CFLT stands at 181.33%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-4.16%
Negative 5Y CAGR while CFLT stands at 181.33%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-4.16%
Negative 3Y CAGR while CFLT stands at 94.92%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
113.23%
10Y OCF/share CAGR at 50-75% of CFLT's 217.67%. Martin Whitman might fear a structural deficiency in operational efficiency.
113.23%
5Y OCF/share CAGR at 50-75% of CFLT's 217.67%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
113.23%
3Y OCF/share CAGR at 50-75% of CFLT's 169.20%. Martin Whitman would suspect weaker recent execution or product competitiveness.
35.56%
Net income/share CAGR at 50-75% of CFLT's 62.89%. Martin Whitman might question if the firm’s product or cost base lags behind.
35.56%
5Y net income/share CAGR at 50-75% of CFLT's 62.89%. Martin Whitman might see a shortfall in operational efficiency or brand power.
35.56%
3Y net income/share CAGR similar to CFLT's 38.07%. Walter Schloss would attribute it to shared growth factors or demand patterns.
169.40%
Equity/share CAGR of 169.40% while CFLT is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
169.40%
Equity/share CAGR of 169.40% while CFLT is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
169.40%
Positive short-term equity growth while CFLT is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.19%
Firm’s AR is declining while CFLT shows 8.23%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
24.51%
We show growth while CFLT is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
2.66%
Asset growth at 75-90% of CFLT's 3.15%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
0.48%
Under 50% of CFLT's 5.30%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-1.91%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-4.92%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-0.63%
We cut SG&A while CFLT invests at 3.04%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.